Can you take Abiraterone with Co-Lav?

Abiraterone has a moderate potential interaction with Arrhythmia.

Abiraterone may cause hypertension, hypokalemia and fluid retention as a consequence of increased mineralocorticoid levels resulting from CYP17 inhibition. Use caution when treating patients whose underlying medical conditions might be compromised by increases in blood pressure, hypokalemia or fluid retention such as patients with heart failure, recent myocardial infarction, ventricular arrhythmias. Use with caution in patients with cardiovascular disease and monitor regularly.

Abiraterone has a moderate potential interaction with Cardiovascular Conditions and Disorders.

Abiraterone may cause hypertension, hypokalemia and fluid retention as a consequence of increased mineralocorticoid levels resulting from CYP17 inhibition. Use caution when treating patients whose underlying medical conditions might be compromised by increases in blood pressure, hypokalemia or fluid retention such as patients with heart failure, recent myocardial infarction, ventricular arrhythmias. Use with caution in patients with cardiovascular disease and monitor regularly.

The polyethylene glycol 3350 with electrolytes in Co-Lav has a moderate potential interaction with Dehydration.

Use caution when prescribing PEG electrolyte solutions to patients with impaired renal function or patients taking concomitant medications that may affect renal function. Ensure adequate hydration and consider performing baseline and post-colonoscopy laboratory tests (electrolytes, creatinine, and BUN) in these patients.

The polyethylene glycol 3350 with electrolytes in Co-Lav has a moderate potential interaction with Esophageal Obstruction.

Patients with impaired gag reflex, unconscious or semi-conscious patients, and patients prone to regurgitation or aspiration should be administered polyethylene glycol (PEG) electrolyte solutions cautiously. Patients experiencing severe bloating, distention or abdominal pain may need to receive PEG electrolyte solutions at a slower rate.

Abiraterone has a moderate potential interaction with Fluid Retention.

Abiraterone may cause hypertension, hypokalemia and fluid retention as a consequence of increased mineralocorticoid levels resulting from CYP17 inhibition. Use caution when treating patients whose underlying medical conditions might be compromised by increases in blood pressure, hypokalemia or fluid retention such as patients with heart failure, recent myocardial infarction, ventricular arrhythmias. Use with caution in patients with cardiovascular disease and monitor regularly.

The polyethylene glycol 3350 with electrolytes in Co-Lav has a major potential interaction with Gastrointestinal Obstruction.

The use of polyethylene glycol (PEG) solutions is contraindicated in patients with gastrointestinal obstruction, perforation, or toxic megacolon. If gastrointestinal obstruction or perforation is suspected, appropriate studies should be performed prior to administration of these agents. Use with caution in patients with severe active ulcerative colitis. Increased activity of the gut caused by these agents could worsen these conditions.

The polyethylene glycol 3350 with electrolytes in Co-Lav has a major potential interaction with Gastrointestinal Obstruction.

The use of laxatives is contraindicated in patients with intestinal obstruction disorders. Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation. Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.

The polyethylene glycol 3350 with electrolytes in Co-Lav has a major potential interaction with Gastrointestinal Perforation.

The use of polyethylene glycol (PEG) solutions is contraindicated in patients with gastrointestinal obstruction, perforation, or toxic megacolon. If gastrointestinal obstruction or perforation is suspected, appropriate studies should be performed prior to administration of these agents. Use with caution in patients with severe active ulcerative colitis. Increased activity of the gut caused by these agents could worsen these conditions.

The polyethylene glycol 3350 with electrolytes in Co-Lav has a moderate potential interaction with Heart Disease.

The use of ionic osmotic laxative products for bowel preparation has been associated with rare reports of serious arrhythmias. Use caution when prescribing PEG electrolyte solutions in patients at increased risk of arrhythmias (e.g., patients with a history of prolonged QT, uncontrolled arrhythmias, recent myocardial infarction, unstable angina, congestive heart failure, or cardiomyopathy). Clinical monitoring of cardiovascular status is recommended prior to, during, and after therapy.

Abiraterone has a moderate potential interaction with History - Myocardial Infarction.

Abiraterone may cause hypertension, hypokalemia and fluid retention as a consequence of increased mineralocorticoid levels resulting from CYP17 inhibition. Use caution when treating patients whose underlying medical conditions might be compromised by increases in blood pressure, hypokalemia or fluid retention such as patients with heart failure, recent myocardial infarction, ventricular arrhythmias. Use with caution in patients with cardiovascular disease and monitor regularly.

Abiraterone has a moderate potential interaction with Hypokalemia.

Abiraterone may cause hypertension, hypokalemia and fluid retention as a consequence of increased mineralocorticoid levels resulting from CYP17 inhibition. Use caution when treating patients whose underlying medical conditions might be compromised by increases in blood pressure, hypokalemia or fluid retention such as patients with heart failure, recent myocardial infarction, ventricular arrhythmias. Use with caution in patients with cardiovascular disease and monitor regularly.

The polyethylene glycol 3350 with electrolytes in Co-Lav has a moderate potential interaction with Hyponatremia.

PEG electrolyte solutions have been associated with seizure activity, and/or loss of consciousness. The seizure cases were associated with electrolyte abnormalities and low serum osmolality. Therapy with these agents should be administered cautiously in patients with a history of or predisposition to seizures or in patients with known or suspected hyponatremia.

The polyethylene glycol 3350 with electrolytes in Co-Lav has a major potential interaction with Inflammatory Bowel Disease.

The use of laxatives is contraindicated in patients with inflammatory bowel disease. Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.

Abiraterone has a major potential interaction with Liver Disease.

Postmarketing studies have associated the use of abiraterone with severe hepatic toxicity, including fulminant hepatitis, acute liver failure and deaths. Serum transaminases and bilirubin levels should be measured before starting treatment and every 2 weeks for the first three months of treatment and then monthly thereafter. Any liver test elevations should prompt more frequently monitoring. Treatment should be discontinued permanently in patients with concurrent elevations of ALT greater than 3 x ULN and total bilirubin greater than 2 x ULN. In patients with baseline moderate hepatic impairment (Child-Pugh Class B), the recommended dose should be reduced to 250 mg once daily. Abiraterone should not be used in patients with severe hepatic impairment (Child-Pugh Class C).

The polyethylene glycol 3350 with electrolytes in Co-Lav has a moderate potential interaction with Renal Dysfunction.

Use caution when prescribing PEG electrolyte solutions to patients with impaired renal function or patients taking concomitant medications that may affect renal function. Ensure adequate hydration and consider performing baseline and post-colonoscopy laboratory tests (electrolytes, creatinine, and BUN) in these patients.

The polyethylene glycol 3350 with electrolytes in Co-Lav has a moderate potential interaction with Seizures.

PEG electrolyte solutions have been associated with seizure activity, and/or loss of consciousness. The seizure cases were associated with electrolyte abnormalities and low serum osmolality. Therapy with these agents should be administered cautiously in patients with a history of or predisposition to seizures or in patients with known or suspected hyponatremia.

The polyethylene glycol 3350 with electrolytes in Co-Lav has a major potential interaction with Ulcerative Colitis.

The use of polyethylene glycol (PEG) solutions is contraindicated in patients with gastrointestinal obstruction, perforation, or toxic megacolon. If gastrointestinal obstruction or perforation is suspected, appropriate studies should be performed prior to administration of these agents. Use with caution in patients with severe active ulcerative colitis. Increased activity of the gut caused by these agents could worsen these conditions.